Literature DB >> 31090452

PPARG Negatively Modulates Six2 in Tumor Formation of Clear Cell Renal Cell Carcinoma.

Yafei Wu1, Tao Song2, Mingwei Liu1, Qingling He1, Lei Chen1, Yamin Liu1, Dongsheng Ni1, Jianing Liu1, Yanxia Hu1, Yuping Gu1, Qianyin Li1, Qin Zhou1, Yajun Xie1.   

Abstract

Substantial research has revealed that peroxisome proliferator-activated receptor-gamma (PPARG) plays a critical role in glucose homeostasis and lipid metabolism, and recent studies have shown different effects in the progression of different tumors. However, the role of PPARG and its target gene in clear cell renal cell carcinoma (ccRCC) are incompletely understood. Clinical data revealed abnormal glucolipid metabolism in primary ccRCC samples. In addition, transcriptional profiling indicated that PPARG expression was positively correlated, whereas Six2 expression was negatively correlated with the overall survival of ccRCC patients. Staining showed that PPARG was mainly expressed in tumor cell cytoplasm, and Six2 was localized to the nuclei. In a ccRCC cell line, PPARG activation promoted cell apoptosis, inhibited cell migration and proliferation, and reduced Six2 expression. Mechanistically, overexpressing Six2 downregulated E-cadherin expression and cell apoptosis, but PPARG activation reversed those effects. Taken together, PPARG promotes apoptosis and suppresses the migration and proliferation of ccRCC cells by inhibiting Six2. These findings reveal that the PPARG/Six2 axis acts as a central pathobiological mediator of ccRCC formation and as a potential therapeutic target for the treatment of patients with ccRCC.

Entities:  

Keywords:  E-cadherin; apoptosis; ccRCC; proliferation

Mesh:

Substances:

Year:  2019        PMID: 31090452     DOI: 10.1089/dna.2018.4549

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  6 in total

1.  Identification of Survival Risk and Immune-Related Characteristics of Kidney Renal Clear Cell Carcinoma.

Authors:  Xiaobin Wu; Yonghui Liang; Xian Chen; Xiangyang Long; Wujun Xu; Li Liu; Binhui Wang; Xiong Zou
Journal:  J Immunol Res       Date:  2022-07-04       Impact factor: 4.493

2.  A New Prognostic Risk Model Based on PPAR Pathway-Related Genes in Kidney Renal Clear Cell Carcinoma.

Authors:  Yingkun Xu; Xiunan Li; Yuqing Han; Zilong Wang; Chenglin Han; Ningke Ruan; Jianyi Li; Xiao Yu; Qinghua Xia; Guangzhen Wu
Journal:  PPAR Res       Date:  2020-09-22       Impact factor: 4.964

3.  53 years old is a reasonable cut-off value to define young and old patients in clear cell renal cell carcinoma: a study based on TCGA and SEER database.

Authors:  Fucai Tang; Zechao Lu; Chengwu He; Hanbin Zhang; Weijia Wu; Zhaohui He
Journal:  BMC Cancer       Date:  2021-05-29       Impact factor: 4.430

4.  Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma.

Authors:  Chi Zhang; Jing-Hui Zheng; Zong-Han Lin; Hao-Yuan Lv; Zhuo-Miao Ye; Yue-Ping Chen; Xiao-Yun Zhang
Journal:  Aging (Albany NY)       Date:  2020-02-09       Impact factor: 5.682

5.  Differential Expression Profiles of the Transcriptome and miRNA Interactome in Synovial Fibroblasts of Rheumatoid Arthritis Revealed by Next Generation Sequencing.

Authors:  Chia-Chun Tseng; Ling-Yu Wu; Wen-Chan Tsai; Tsan-Teng Ou; Cheng-Chin Wu; Wan-Yu Sung; Po-Lin Kuo; Jeng-Hsien Yen
Journal:  Diagnostics (Basel)       Date:  2019-08-18

6.  Quantitative assessment of the association of polymorphisms in the metallothionein 2A gene with cancer risk.

Authors:  Jianguo Wang; Pinghua Huang; Wei Zhao; Wei Ren; Ling Ai; Liping Wu
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.